Gentile et al reported the Survival Risk Score for Ibrutinib for evaluating a patient with relapsed or refractory chronic lymphocytic leukemia who is treated with ibrutinib. The authors are from multiple institutions in Italy and Israel.
Patient selection: relapsed or refractory chronic lymphocytic leukemia treated with ibrutinib
Outcome: overall survival
Parameters:
(1) hemoglobin in g/L and sex
(2) serum beta-2 microglobulin in mg/L
(3) serum LDH and upper limit of normal, in IU/L
Parameter
Finding
Points
hemoglobin and sex
>= 110 g/L, female
0
< 110 g/L, female
2
>= 120 g/L, male
0
< 120 g/L, male
2
serum beta-2 microglobulin
< 5 mg/L
0
>= 5 mg/L
1
serum LDH
<= ULN
0
> ULN
2
total score =
= SUM(points for all 3 parameters)
Interpretation:
• minimum score: 0
• maximum score: 5
Total Score
Risk Group
2-Year Overall Survival
0
low
95%
1 to 3
intermediate
81%
4 or 5
high
61%
To read more or access our algorithms and calculators, please log in or register.
